Capsule

Abstract

The utility model provides a capsule. The capsule comprises a first capsule shell, a second capsule shell and a buckling ring structure, the first capsule shell is provided with a first open end and a first closed end. The second capsule shell is correspondingly connected with the first capsule shell, and the second capsule shell is provided with a second open end and a second closed end. The buckling ring structure is arranged on the first capsule shell and the second capsule shell. Therefore, additives in the capsule can be prevented from overflowing out of the capsule, and air, moisture, digestive juice or other substances outside the capsule can be effectively prevented from entering the capsule through gaps.

Description

Technical Field

[0001] The present disclosure relates to a capsule, and in particular to a capsule with a suitable snap-fit ​​effect. Background Art

[0002] Capsules are often used as delivery vehicles for drugs or nutritional supplements. They can be loaded with a single drug or multiple drugs or nutritional supplements to mask the special taste of the drugs or nutritional supplements, or to protect the added drugs or nutritional supplements from contact with water, air, digestive juices or other substances outside the capsule, and the additives are released and absorbed only after reaching the small intestine.

[0003] Among the numerous capsule products on the market, the most basic capsule structure includes two capsule shells, which are combined to form an internal space to accommodate additives such as medicines or nutritional supplements. However, the two capsule shells in this most basic structure may have gaps at the combination point and cannot be completely sealed. The air, moisture, digestive juice or other substances outside the capsule can enter the capsule through the gaps, causing the internal additives to become damp, deteriorate or decompose. On the other hand, the two capsule shells may also rotate relative to each other or separate in opposite directions due to external forces, causing the additives inside the capsule to spill. Whether the substances outside the capsule enter the capsule, or the additives inside the capsule spill out of the capsule, the capsule may not be able to fully exert its intended effect.

[0004] Then, a latch-like annular buckle structure appeared to engage the two capsule shells with each other, which could prevent the two capsule shells from separating in the opposite direction, but the concerns about tightness and rotation were still not resolved. There are also annular sealing band structures designed at the joints of the two capsule shells, or a film coating structure wrapped around the outermost part of the whole capsule to directly block the air, moisture, digestive juice or other substances outside the capsule from entering the capsule through the gap, but there is still a risk of damage. For example, during the process of packaging the capsule, it may rub and collide with other capsules, machines or containers, or the consumer may scratch or damage the annular sealing band structure or film coating structure during the process of taking it, so that the structure cannot fully protect the state of the capsule, and the air, moisture, digestive juice or other substances outside the capsule still have the possibility of entering the capsule through the gap. Utility Model Content

[0005] The capsule provided by the present disclosure includes a buckle ring structure, which can prevent the additive in the capsule from spilling and avoid the first capsule shell and the second capsule shell from being easily pulled apart or separated when opposite forces are applied to the first capsule shell and the second capsule shell or the capsule is squeezed by external forces. When a specific condition range is met, the buckle ring structure has a more appropriate buckling effect, while the buckle ring structure outside the specific condition range will not be able to buckle effectively and will produce a larger gap, and increase the manufacturing cost.

[0006] According to one embodiment of the present disclosure, a capsule is provided, comprising a first capsule shell, a second capsule shell, a buckle ring structure and a viscose structure. The first capsule shell has a first open end and a first closed end. The second capsule shell is connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end. The buckle ring structure is disposed on the first capsule shell and the second capsule shell. The viscose structure is located in an overlapped area between the first capsule shell and the second capsule shell. The maximum width of the buckle ring structure is Wcmax, the maximum length of the first capsule shell is W1, the maximum length of the second capsule shell is W2, and the width of the overlapped area between the first capsule shell and the second capsule shell is Wo12, which satisfies the following conditions: 0≤Wcmax / (W1+W2-Wo12)≤2.

[0007] According to another embodiment of the present disclosure, a capsule is provided, comprising a first capsule shell, a second capsule shell, a buckling ring structure, an internal space and at least one additive. The first capsule shell has a first open end and a first closed end. The second capsule shell is correspondingly connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end. The buckling ring structure is disposed on the first capsule shell and the second capsule shell. The internal space is formed by the corresponding connection of the first capsule shell and the second capsule shell. At least one additive is accommodated in the internal space, and at least one additive includes at least one particle. The maximum width of the buckling ring structure is Wcmax, the maximum length of the first capsule shell is W1, the maximum length of the second capsule shell is W2, and the width of an overlapping area between the first capsule shell and the second capsule shell is Wo12, which satisfies the following conditions: <Wcmax / (W1+W2-Wo12)≤0.4。 BRIEF DESCRIPTION OF THE DRAWINGS

[0008] In order to make the above and other objects, features, advantages and embodiments of the present disclosure more clearly understood, the accompanying drawings are described as follows:

[0009] Figure 1 is a schematic diagram illustrating a capsule according to a first embodiment of the present disclosure;

[0010] Figure 2 is a schematic diagram illustrating a capsule according to a second embodiment of the present disclosure;

[0011] Figure 3 is a schematic diagram illustrating a capsule according to a third embodiment of the present disclosure;

[0012] Figure 4 is a schematic diagram illustrating a capsule according to a fourth embodiment of the present disclosure;

[0013] Figure 5 is a schematic diagram illustrating a capsule according to a fifth embodiment of the present disclosure;

[0014] Figure 6is a schematic diagram illustrating a capsule according to a sixth embodiment of the present disclosure;

[0015] Figure 7 is a schematic diagram illustrating a capsule according to a seventh embodiment of the present disclosure;

[0016] Figure 8 is a schematic diagram illustrating a capsule according to an eighth embodiment of the present disclosure;

[0017] Fig. 9 is a schematic diagram illustrating a capsule according to a ninth embodiment of the present disclosure;

[0018] Fig.10 is a schematic diagram illustrating a capsule according to a tenth embodiment of the present disclosure;

[0019] Fig.11 is a schematic diagram illustrating a capsule according to the eleventh embodiment of the present disclosure; and

[0020] Fig.12 FIG. 1 is a schematic diagram illustrating a capsule according to the twelfth embodiment of the present disclosure.

[0021]

Explanation of symbols

[0022] 100,200,300,400,500,600,700,800,900,1000,1100,1200:Capsules

[0023] 101,201,301,401,501,601,701,801,901,1001,1101,1201: internal space 102,202,302,402,502,602,702,802,902,1002,1102,1202: additives

[0024] 110,210,310,410,510,610,710,810,910,1010,1110,1210: first capsule shell 111,211,311,411,511,611,711,811,911,1011,1111,1211: first open end 112,212,312,412,512,612,712,812,912,1012,1112,1212: first closed end 113,313,413,513,713,813,913,1013,1113,1213: first rotation stop point

[0025] 120,220,320,420,520,620,720,820,920,1020,1120,1220: second capsule shell 121,221,321,421,521,621,721,821,921,1021,1121,1221: second open end 122,222,322,422,522,622,722,822,922,1022,1122,1222: second closed end 123,323,423,523,723,823,923,1023,1123,1223: second rotation stop point

[0026] 130,230,330,430,530,630,730,830,930,1030,1130,1230: buckle ring structure 131,231,331,431,531,631,731,831,931,1031,1131,1231: first buckle ring 132,232,332,432,532,632,732,832,932,1032,1132,1232: second buckle ring 140,240,340,440,540,640,740,840,940,1040: adhesive structure

[0027] W1: Maximum length of the first capsule shell

[0028] D1: outer diameter of the first open end of the first capsule shell

[0029] W2: Maximum length of the second capsule shell

[0030] D2: outer diameter of the second open end of the second capsule shell

[0031] Wgl: Width of the adhesive structure

[0032] Wo12: The width of the overlap area between the first capsule shell and the second capsule shell

[0033] Dcmin: Minimum diameter of the snap ring structure

[0034] Wcmax: Maximum width of the snap ring structure

[0035] N1: the number of the first rotation stop points of the first capsule shell

[0036] N2: the number of the second rotation stop points of the second capsule shell DETAILED DESCRIPTION

[0037] An embodiment of the present disclosure provides a capsule, comprising a first capsule shell, a second capsule shell, a snap ring structure, and an adhesive structure. The first capsule shell has a first open end and a first closed end. The second capsule shell is correspondingly connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end. The snap ring structure is disposed on the first capsule shell and the second capsule shell. The adhesive structure is located in an overlapping area between the first capsule shell and the second capsule shell. Thereby, the snap ring structure of the capsule according to the present disclosure can prevent the additives in the capsule from spilling, and avoid easily pulling or separating the first capsule shell and the second capsule shell when applying opposite-direction forces on the first capsule shell and the second capsule shell or when the capsule is extruded by an external force. Moreover, the adhesive structure can block air, moisture, digestive juice or other substances outside the capsule from entering the capsule through the gap, and can also prevent the additives inside the capsule from spilling outside the capsule, so that the additives in the capsule according to the present disclosure are released only after reaching the small intestine to facilitate human absorption and exert their intended effects.

[0038] Another embodiment of the present disclosure provides a capsule, comprising a first capsule shell, a second capsule shell, a snap ring structure, an internal space, and at least one additive. The first capsule shell has a first open end and a first closed end. The second capsule shell is correspondingly connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end. The snap ring structure is disposed on the first capsule shell and the second capsule shell. The internal space is formed by the corresponding connection of the first capsule shell and the second capsule shell. At least one additive is accommodated in the internal space. Thereby, the snap ring structure of the capsule according to the present disclosure can prevent the additives in the capsule from spilling, and avoid easily pulling or separating the first capsule shell and the second capsule shell when applying opposite-direction forces on the first capsule shell and the second capsule shell or when the capsule is extruded by an external force.

[0039] The maximum width of the snap ring structure is Wcmax, the maximum length of the first capsule shell is W1, the maximum length of the second capsule shell is W2, and the width of the overlapping area between the first capsule shell and the second capsule shell is Wo12, which can satisfy the following conditions: 0 ≤ Wcmax / (W1 + W2 - Wo12) ≤ 2. Thereby, the snap ring structure within the condition range has a more appropriate snap effect. Outside the condition range, the snap ring structure cannot be effectively snapped, resulting in a larger gap and increasing the manufacturing cost. Or, it can satisfy the following conditions: 0 < Wcmax / (W1 + W2 - Wo12) ≤ 0.4. Or, it can satisfy the following conditions: 0 ≤ Wcmax / (W1 + W2 - Wo12) ≤ 1.5. Or, it can satisfy the following conditions: 0 ≤ Wcmax / (W1 + W2 - Wo12) ≤ 1. Or, it can satisfy the following conditions: 0 ≤ Wcmax / (W1 + W2 - Wo12) ≤ 0.5. Or, it can satisfy the following conditions: 0 ≤ Wcmax / (W1 + W2 - Wo12) ≤ 0.1.

[0040] The first capsule shell may include at least one first anti-rotation point, and the second capsule shell may include at least one second anti-rotation point. Thereby, in addition to preventing the first capsule shell and the second capsule shell from separating in opposite directions, the arrangement of the first anti-rotation point and the second anti-rotation point can also prevent the first capsule shell and the second capsule shell from rotating relative to each other.

[0041] The first anti-rotation point of the first capsule shell may be recessed towards the interior of the capsule, and the second anti-rotation point of the second capsule shell may be recessed towards the interior of the capsule. Thereby, when the first anti-rotation point of the first capsule shell is combined and fastened with the second anti-rotation point of the second capsule shell, it can prevent the first capsule shell and the second capsule shell from separating in opposite directions, and can also make it difficult for the first capsule shell and the second capsule shell to rotate relative to each other.

[0042] The number of the first anti-rotation points of the first capsule shell is N1, and the number of the second anti-rotation points of the second capsule shell is N2, which may satisfy the following conditions: 0 ≤ N1 + N2 ≤ 20. Thereby, controlling the number of the first anti-rotation points and the second anti-rotation points can effectively exert the sealing effect and reduce the manufacturing cost of the capsule. Or, it may satisfy the following conditions: 1 ≤ N1 + N2 ≤ 20. Or, it may satisfy the following conditions: 1 ≤ N1 + N2 ≤ 12. Or, it may satisfy the following conditions: 1 ≤ N1 + N2 ≤ 10. Or, it may satisfy the following conditions: 1 ≤ N1 + N2 ≤ 8.

[0043] The snap ring structure may include a first snap ring and a second snap ring. The first snap ring is disposed on the first capsule shell, and the second snap ring is disposed on the second capsule shell. The outer diameter of the first open end of the first capsule shell is D1, and the minimum diameter of the snap ring structure is Dcmin, which may satisfy the following conditions: 0 < Dcmin / D1 < 1. Thereby, the snap ring structure within the range of the foregoing conditions can maintain the shape of the capsule, and the snap ring structure outside the range of the foregoing conditions will cause the internal space of the capsule to shrink, which is not conducive to swallowing by the consumer. Or, it may satisfy the following conditions: 0 < Dcmin / D1 ≤ 0.9. Or, it may satisfy the following conditions: 0 < Dcmin / D1 ≤ 0.8. Or, it may satisfy the following conditions: 0 < Dcmin / D1 ≤ 0.6. Or, it may satisfy the following conditions: 0 < Dcmin / D1 ≤ 0.4.

[0044] The width of the adhesive structure is Wgl, and the width of the overlapping area between the first capsule shell and the second capsule shell is Wo12, which can meet the following conditions: 0 < Wgl / Wo12 ≤ 5. Thereby, the adhesive structure can prevent air, moisture, digestive juices, or other substances outside the capsule from entering the capsule, and can also prevent the additives inside the capsule from spilling out of the capsule. The adhesive structure within the range of meeting the aforementioned conditions can have better sealing performance. The adhesive structure outside the aforementioned conditions has insufficient sealing performance and increases the manufacturing cost of the capsule. Or, it can meet the following conditions: 0 ≤ Wgl / Wo12 ≤ 4. Or, it can meet the following conditions: 0 ≤ Wgl / Wo12 ≤ 2. Or, it can meet the following conditions: 0 ≤ Wgl / Wo12 ≤ 1. Or, it can meet the following conditions: 0 ≤ Wgl / Wo12 ≤ 0.5.

[0045] The capsule may further include an internal space and at least one additive. At least one additive is accommodated in the internal space, and at least one additive may include at least one particle. At least one particle can be a sleep aid ingredient particle, an anti-aging ingredient particle, an eye care ingredient particle, a weight loss ingredient particle, a liver protection ingredient particle, or a cardiovascular benefit ingredient particle. Thereby, the capsule can achieve its edible purpose with the additive.

[0046] At least one particle can be an eye care ingredient particle. Thereby, the eye care ingredient particle has the effect of antioxidant for the eyes or repairing the macula.

[0047] At least one particle can be a weight loss ingredient particle. Thereby, the weight loss ingredient particle has the effect of promoting combustion metabolism, inhibiting sugar absorption, or controlling appetite.

[0048] At least one particle can be a liver protection ingredient particle. Thereby, the liver protection ingredient particle has the effect of antioxidant, anti-inflammatory, or enhancing immunity.

[0049] At least one particle can be a sleep aid ingredient particle. Thereby, the sleep aid ingredient particle has the effect of improving difficulty in falling asleep or poor sleep quality.

[0050] At least one particle can be an anti-aging ingredient particle. Thereby, the anti-aging ingredient particle has the effect of refreshing or preventing aging.

[0051] At least one particle can be a cardiovascular benefit ingredient particle. Thereby, the cardiovascular benefit ingredient particle has the effect of lowering blood sugar and blood lipids, dissolving blood clots, antiplatelet aggregation, or maintaining vascular endothelial function.

[0052] The capsule may further include a film coating structure, and the film coating structure is disposed on the outer sides of the first capsule shell and the second capsule shell. Thereby, the film coating structure can further protect the capsule, prevent external air, moisture, or impurities from entering the capsule, and has the effects of moisture-proof and anti-decomposition.

[0053] The maximum length of the first capsule shell is W1, which may satisfy the following conditions: 7mm≤W1≤15mm. In this way, it is prevented that the capsule is too long and is not conducive to swallowing. Alternatively, it may satisfy the following conditions: 8mm≤W1≤14mm. Alternatively, it may satisfy the following conditions: 9mm≤W1≤13.5mm. Alternatively, it may satisfy the following conditions: 10mm≤W1≤13mm. Alternatively, it may satisfy the following conditions: 10.5mm≤W1≤12.5mm.

[0054] The outer diameter of the first opening end of the first capsule shell is D1, which may satisfy the following conditions: 4.5 mm ≤ D1 ≤ 12 mm. In this way, the outer diameter of the capsule is prevented from being too wide and not conducive to swallowing by the consumer. Alternatively, it may satisfy the following conditions: 5 mm ≤ D1 ≤ 10 mm. Alternatively, it may satisfy the following conditions: 5.5 mm ≤ D1 ≤ 9.5 mm. Alternatively, it may satisfy the following conditions: 6 mm ≤ D1 ≤ 9 mm. Alternatively, it may satisfy the following conditions: 6.5 mm ≤ D1 ≤ 8.5 mm.

[0055] The maximum length of the second capsule shell is W2, which may satisfy the following conditions: 14 mm ≤ W2 ≤ 21 mm. This prevents the capsule from being too long and making it difficult for the consumer to swallow. Alternatively, it may satisfy the following conditions: 15 mm ≤ W2 ≤ 20 mm. Alternatively, it may satisfy the following conditions: 15.5 mm ≤ W2 ≤ 19.5 mm. Alternatively, it may satisfy the following conditions: 16 mm ≤ W2 ≤ 19 mm. Alternatively, it may satisfy the following conditions: 16.5 mm ≤ W2 ≤ 18.5 mm.

[0056] The outer diameter of the second opening end of the second capsule shell is D2, which may satisfy the following conditions: 4.5 mm ≤ D2 ≤ 12 mm. In this way, the outer diameter of the capsule is prevented from being too wide and not conducive to swallowing by the consumer. Alternatively, it may satisfy the following conditions: 5 mm ≤ D2 ≤ 10 mm. Alternatively, it may satisfy the following conditions: 5.5 mm ≤ D2 ≤ 9.5 mm. Alternatively, it may satisfy the following conditions: 6 mm ≤ D2 ≤ 9 mm. Alternatively, it may satisfy the following conditions: 6.5 mm ≤ D2 ≤ 8.5 mm.

[0057] The width of the viscose structure is Wgl, which can meet the following conditions: 0mm≤Wgl≤10mm. In this way, air, moisture, digestive juice or other substances outside the capsule can be prevented from entering the capsule through the gap, or additives inside the capsule can be prevented from spilling out of the capsule. Alternatively, it can meet the following conditions: 0.5mm≤Wgl≤9.5mm. Alternatively, it can meet the following conditions: 1mm≤Wgl≤8mm. Alternatively, it can meet the following conditions: 3mm≤Wgl≤7.5mm. Alternatively, it can meet the following conditions: 3.5mm≤Wgl≤4.5mm.

[0058] The width of the overlapping region between the first capsule shell and the second capsule shell is Wo12, which can satisfy the following conditions: 1 mm ≤ Wo12 ≤ 12 mm. Thereby, it is ensured that the first capsule shell and the second capsule shell can be combined to form a capsule. Or, it can satisfy the following conditions: 2 mm ≤ Wo12 ≤ 11 mm. Or, it can satisfy the following conditions: 3 mm ≤ Wo12 ≤ 10 mm. Or, it can satisfy the following conditions: 4 mm ≤ Wo12 ≤ 8 mm. Or, it can satisfy the following conditions: 5 mm ≤ Wo12 ≤ 7 mm.

[0059] The outer diameter of the first open end of the first capsule shell is D1, and the outer diameter of the second open end of the second capsule shell is D2, which can satisfy the following conditions: 1 < D1 / D2 ≤ 1.1. Thereby, it is ensured that the first capsule shell and the second capsule shell can be combined to form a capsule, and the gap between the first capsule shell and the second capsule shell will not be too large. Or, it can satisfy the following conditions: 1.005 ≤ D1 / D2 ≤ 1.09. Or, it can satisfy the following conditions: 1.01 ≤ D1 / D2 ≤ 1.07. Or, it can satisfy the following conditions: 1.02 ≤ D1 / D2 ≤ 1.06. Or, it can satisfy the following conditions: 1.03 ≤ D1 / D2 ≤ 1.05.

[0060] The width of the overlapping region between the first capsule shell and the second capsule shell is Wo12, and the maximum length of the first capsule shell is W1, which can satisfy the following conditions: 0.2 ≤ Wo12 / W1 ≤ 0.9. Thereby, it is avoided that the overlapping range of the first capsule shell and the second capsule shell is too large, increasing the manufacturing cost of the capsule. Or, it can satisfy the following conditions: 0.3 ≤ Wo12 / W1 ≤ 0.85. Or, it can satisfy the following conditions: 0.4 ≤ Wo12 / W1 ≤ 0.8. Or, it can satisfy the following conditions: 0.5 ≤ Wo12 / W1 ≤ 0.75. Or, it can satisfy the following conditions: 0.6 ≤ Wo12 / W1 ≤ 0.7.

[0061] The width of the overlapping region between the first capsule shell and the second capsule shell is Wo12, and the maximum length of the second capsule shell is W2, which can satisfy the following conditions: 0.2 ≤ Wo12 / W2 ≤ 0.9. Thereby, it is avoided that the overlapping range of the first capsule shell and the second capsule shell is too large, increasing the manufacturing cost of the capsule. Or, it can satisfy the following conditions: 0.25 ≤ Wo12 / W2 ≤ 0.8. Or, it can satisfy the following conditions: 0.3 ≤ Wo12 / W2 ≤ 0.7. Or, it can satisfy the following conditions: 0.35 ≤ Wo12 / W2 ≤ 0.6. Or, it can satisfy the following conditions: 0.4 ≤ Wo12 / W2 ≤ 0.5.

[0062] The minimum diameter of the buckle ring structure is Dcmin, which can meet the following conditions: 4mm≤Dcmin≤13mm. In this way, the buckle ring structure is prevented from compressing the internal space of the capsule or affecting the smoothness of swallowing by the consumer. Alternatively, it can meet the following conditions: 4.5mm≤Dcmin≤11mm. Alternatively, it can meet the following conditions: 5mm≤Dcmin≤10mm. Alternatively, it can meet the following conditions: 6mm≤Dcmin≤9mm. Alternatively, it can meet the following conditions: 7mm≤Dcmin≤8mm.

[0063] The maximum width of the buckle ring structure is Wcmax, which can meet the following conditions: 0mm≤Wcmax≤10mm. In this way, the buckle ring structure is prevented from compressing the internal space of the capsule or affecting the smoothness of swallowing by the consumer. Alternatively, it can meet the following conditions: 0mm≤Wcmax≤5mm. Alternatively, it can meet the following conditions: 0mm≤Wcmax≤3mm. Alternatively, it can meet the following conditions: 0mm≤Wcmax≤2mm. Alternatively, it can meet the following conditions: 0mm≤Wcmax≤1mm.

[0064] The maximum width of the buckle ring structure is Wcmax, and the width of the overlapping area between the first capsule shell and the second capsule shell is Wo12, which can meet the following conditions: 0≤Wcmax / Wo12<1. In this way, when the first capsule shell and the second capsule shell are subjected to forces in opposite directions or the capsule is squeezed by external forces, the first capsule shell and the second capsule shell can be easily pulled apart or separated. Alternatively, it can meet the following conditions: 0≤Wcmax / Wo12≤0.5. Alternatively, it can meet the following conditions: 0≤Wcmax / Wo12≤0.3. Alternatively, it can meet the following conditions: 0≤Wcmax / Wo12≤0.2. Alternatively, it can meet the following conditions: 0≤Wcmax / Wo12≤0.1.

[0065] The capsule described in the present disclosure is a combination of a first capsule shell and a second capsule shell. The shape of the capsule can be a cylinder. In the combined state, the capsule shell composed of the first capsule shell and the second capsule shell is used as a boundary to be divided into a capsule interior and a capsule exterior. The capsule interior has an internal space for accommodating additives. The cross section of the first open end of the first capsule shell is approximately circular, the first closed end of the first capsule shell is a surface shape that bulges outward from the capsule and has a curvature, and the maximum length of the first capsule shell is the vertical distance between the most protruding point of the first closed end of the first capsule shell and the cross section of the first open end of the first capsule shell. The cross section of the second open end of the second capsule shell is approximately circular, the second closed end of the second capsule shell is a surface shape that bulges outward from the capsule and has a curvature, and the maximum length of the second capsule shell is the vertical distance between the most protruding point of the closed end of the second capsule shell and the cross section of the second open end of the second capsule shell. The outer diameter of the first open end of the first capsule shell is greater than the outer diameter of the second open end of the second capsule shell, so that in the combined state of the capsule, the positional relationship between the first capsule shell and the second capsule shell is that the first capsule shell is located outside the second capsule shell, and the overlapping range of the first capsule shell and the second capsule shell is the overlap area.

[0066] The buckle ring structure described in the present disclosure may include a first buckle ring located in the first capsule shell and a second buckle ring located in the second capsule shell. The first buckle ring and the second buckle ring may be annular structures protruding to the outside of the capsule or annular structures recessed to the inside of the capsule. The measurement reference point of the maximum width of the buckle ring structure is the two end points where the buckle ring structure begins to have a curvature change, and the measurement reference point of the minimum diameter of the buckle ring structure is the diameter of the circle formed by all the most recessed points on the buckle ring structure. The first buckle ring may protrude to the outside of the capsule or recessed to the inside of the capsule. The second buckle ring may protrude to the outside of the capsule or recessed to the inside of the capsule. The first buckle ring protruding to the outside of the capsule and the second buckle ring protruding to the outside of the capsule can be combined and buckled together. Or. The first buckle ring recessed to the inside of the capsule and the second buckle ring recessed to the inside of the capsule can be combined and buckled together.

[0067] The anti-rotation point described in the present disclosure may include a first anti-rotation point on the first capsule shell and a second anti-rotation point on the second capsule shell. The first anti-rotation point on the first capsule shell may be circular, triangular, square, elliptical, long and stick-shaped or other geometric shapes. The number of the first anti-rotation points on the first capsule shell is calculated as one circle, and all the first anti-rotation points on the first capsule shell may uniformly protrude toward the outside of the capsule or uniformly be recessed toward the inside of the capsule. The second anti-rotation point on the second capsule shell may be circular, square or elliptical. The number of the second anti-rotation points on the second capsule shell is calculated as one circle, and all the second anti-rotation points on the second capsule shell may uniformly protrude toward the outside of the capsule or uniformly be recessed toward the inside of the capsule. The first anti-rotation point of the first capsule shell and the second anti-rotation point of the second capsule shell are consistent in shape and concave-convex direction, so that the first anti-rotation point on the first capsule shell and the second anti-rotation point on the second capsule shell can be combined and buckled with each other.

[0068] The adhesive structure described in the present disclosure is located in the overlapped area between the first capsule shell and the second capsule shell, and can be coated on the inner side of the first capsule shell or the outer side of the second capsule shell.

[0069] The capsule described in the present disclosure contains additives classified by function, and the additives may include at least one particle, which may be eye protection ingredient particles, weight loss ingredient particles, liver protection ingredient particles, sleep-promoting ingredient particles, anti-aging ingredient particles or cardiovascular benefit ingredient particles, and the additives may be accommodated in the internal space.

[0070] The eye protection ingredient particles described in the present disclosure may include phycoerythrin, anthocyanin, lutein, zeaxanthin, vitamin A, vitamin E or crocin and combinations thereof.

[0071] The weight loss ingredient particles disclosed herein may include oligosaccharides, inulin, L-carnitine, alkaloids, capsaicin, catechins, plant saponins, chitosan, tannic acid, chlorogenic acid, chromium nicotinate, conjugated linoleic acid or white kidney beans and combinations thereof, and may also be guarana extracts.

[0072] The liver protection component particles described in the present disclosure may include sesamin, curcumin, cynarin, quinoa B complex, quinoa B12, β-(1,3 / 1,6)-glucan, triterpenoid compounds, reduced coenzyme Q10 or olive acid and combinations thereof, and may also be ganoderma lucidum extract.

[0073] The sleep-relief ingredient particles disclosed herein may include GABA, sesamin, tryptophan, calcium or magnesium, and combinations thereof, or may be chamomile extract, jujube seed extract, or sour cherry extract, and combinations thereof.

[0074] The anti-aging ingredient particles described in the present disclosure may include β-nicotinamide mononucleotide, OPC proanthocyanidin, superoxide dismutase, glutathione, vitamin C, vitamin E or β-carotene and combinations thereof.

[0075] The cardiovascular benefit ingredient particles described in the present disclosure may include red yeast rice, fish oil, nattokinase, coenzyme Q10 or astaxanthin and combinations thereof.

[0076] The capsule described in the present disclosure contains additives classified by type, and the additives may include at least one particle, and the particles may include probiotic particles, algae particles, protein particles, vitamin particles, phenol particles, carbohydrate particles, traditional Chinese medicine particles, trace element particles, and organic pigment particles. The internal space can accommodate the additives.

[0077] The probiotic particles described in the present disclosure may include Bifidobacterium animalis, Rhizoctonia bisphidii, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus sporeans, or Lactococcus lactis, and combinations thereof.

[0078] The algae particles described in the present disclosure may include organic seaweed, Aphanizomenon, Tussauds, red algae or green algae and combinations thereof.

[0079] The protein particles described in the present disclosure may include whey protein, collagen, Q10 coenzyme, L-carnitine, protein peptides, proteoglycans, casein macropeptides, arginine, glutamic acid, glutamic acid or arginine, and combinations thereof.

[0080] The vitamin particles described in the present disclosure may include vitamin A, vitamin B group, vitamin C, vitamin D, vitamin E, vitamin K or quinoa B group and combinations thereof.

[0081] The phenolic particles described in the present disclosure may include tea polyphenols, olive polyphenols, thistle polyphenols, indoxyl sulfate p-cresol or tannic acid and combinations thereof.

[0082] The carbohydrate particles described in the present disclosure may include chitosan, cellulose, mannose, dextrin, oligosaccharides, inulin, dextran, glucosamine, chicory fiber or ribose, and combinations thereof.

[0083] The Chinese medicinal particles of the capsule described in the present disclosure may include Antrodia cinnamomea, Cordyceps sinensis, Licorice, Angelica sinensis, Astragalus, Schisandra chinensis, White Peony Root, American Ginseng, Chuanxiong, Deer Antler, Lycium barbarum, Crataegus pinnatifida, Ginseng, Salvia miltiorrhiza, Codonopsis pilosula, Scrophularia ningpoensis, Rehmannia glutinosa, Rhodiola rosea, Ligustrum lucidum, Eucommia ulmoides Leaf, Poria cocos, Tangerine peel, Cassia seed, Platycodon grandiflorum, Cnidium monnieri, Ziziphus jujuba seed, Atractylodes macrocephala, Rhizoma Chuanxiong, Flos Lonicerae, Houttuynia cordata, Pleurotus eryngii, Gallnut, Enoki mushroom, Citrus aurantium, Polygala tenuifolia, Ganoderma lucidum, Leonurus japonicus, Euryale ferox, Cordyceps militaris seed, Kuding or Acanthopanax senticosus and combinations thereof.

[0084] The trace element particles described in the present disclosure may include zinc, selenium, magnesium, chromium, calcium or iron and combinations thereof.

[0085] The organic pigment particles described in the present disclosure may include lutein, zeaxanthin, α-carotene, β-carotene, lycopene, crocin, anthocyanin or astaxanthin, and combinations thereof.

[0086] The particles described in the present disclosure may be in powder form.

[0087] The various technical features of the capsule disclosed above can be configured in combination to achieve corresponding effects.

[0088] According to the above implementation modes, specific embodiments are proposed below and described in detail with reference to the accompanying drawings.

[0089] <First Embodiment>

[0090] Please refer to Figure 1, which is a schematic diagram of a capsule 100 according to the first embodiment of the present disclosure. The capsule 100 comprises a first capsule shell 110 , a second capsule shell 120 , a buckling ring structure 130 , an adhesive structure 140 and an additive 102 .

[0091] The first capsule shell 110 has a first open end 111 and a first closed end 112 .

[0092] The second capsule shell 120 is correspondingly connected to the first capsule shell 110 , wherein the second capsule shell 120 has a second open end 121 and a second closed end 122 , and the first open end 111 of the first capsule shell 110 is correspondingly connected to the second open end 121 of the second capsule shell 120 to form an internal space 101 .

[0093] The buckle ring structure 130 is disposed on the first capsule shell 110 and the second capsule shell 120. Specifically, the buckle ring structure 130 includes a first buckle ring 131 and a second buckle ring 132, the first buckle ring 131 is disposed on the first capsule shell 110, and the second buckle ring 132 is disposed on the second capsule shell 120. The first buckle ring 131 is an annular structure recessed toward the inside of the capsule 100, and the second buckle ring 132 is also an annular structure recessed toward the inside of the capsule 100, and the first buckle ring 131 and the second buckle ring 132 can be assembled and buckled together to form the buckle ring structure 130.

[0094] The first capsule shell 110 may include at least one first rotation stop point 113, and the second capsule shell 120 may include at least one second rotation stop point 123, wherein the first rotation stop point 113 is recessed toward the interior of the capsule 100, and the second rotation stop point 123 is recessed toward the interior of the capsule 100, so that the first rotation stop point 113 on the first capsule shell 110 and the second rotation stop point 123 on the second capsule shell 120 can be combined and buckled with each other. Furthermore, in the capsule 100, the number of the first rotation stop point 113 is one, and the number of the second rotation stop point 123 is one.

[0095] The adhesive structure 140 is located in an overlapped area (not shown) between the first capsule shell 110 and the second capsule shell 120. In the capsule 100, the number of the adhesive structure 140 is one.

[0096] In the capsule 100 , the adhesive structure 140 is disposed in the overlapped area and close to the second open end 121 of the second capsule shell 120 , and the buckle ring structure 130 is disposed adjacent to the adhesive structure 140 and further away from the second open end 121 of the second capsule shell 120 than the adhesive structure 140 .

[0097] The additive 102 is contained in the inner space 101 , and the additive 102 includes at least one particle.

[0098] Please also refer to Figure 1Table 1A shows parameter values ​​of the capsule 100 according to the first embodiment.

[0099]

[0100] In Table 1A, W1 is the maximum length of the first capsule shell 110, D1 is the outer diameter of the first open end 111 of the first capsule shell 110, W2 is the maximum length of the second capsule shell 120, D2 is the outer diameter of the second open end 121 of the second capsule shell 120, Wgl is the width of the viscose structure 140, Wo12 is the width of the overlapping area between the first capsule shell 110 and the second capsule shell 120, Dcmin is the minimum diameter of the buckling ring structure 130, Wcmax is the maximum width of the buckling ring structure 130, N1 is the number of first stop points 113 of the first capsule shell 110, and N2 is the number of second stop points 123 of the second capsule shell 120.

[0101] If the definitions of the data in the tables of the following embodiments are the same as those in Table 1A, they will not be repeated here.

[0102] Please refer to Table 1B, which shows the types and compositions of the particles of the additive 102 of the capsule 100 of the first embodiment, wherein the additive 102 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0103]

[0104]

[0105] <Second Embodiment>

[0106] Please refer to Figure 2 , which is a schematic diagram of a capsule 200 according to the second embodiment of the present disclosure. The capsule 200 comprises a first capsule shell 210, a second capsule shell 220, a buckling ring structure 230, an adhesive structure 240 and an additive 202.

[0107] The first capsule shell 210 has a first open end 211 and a first closed end 212 .

[0108] The second capsule shell 220 is correspondingly connected to the first capsule shell 210 , wherein the second capsule shell 220 has a second open end 221 and a second closed end 222 , and the first open end 211 of the first capsule shell 210 is correspondingly connected to the second open end 221 of the second capsule shell 220 to form an internal space 201 .

[0109] The buckle ring structure 230 is disposed on the first capsule shell 210 and the second capsule shell 220. Specifically, the buckle ring structure 230 includes a first buckle ring 231 and a second buckle ring 232, the first buckle ring 231 is disposed on the first capsule shell 210, and the second buckle ring 232 is disposed on the second capsule shell 220. The first buckle ring 231 is an annular structure recessed toward the inside of the capsule 200, and the second buckle ring 232 is also an annular structure recessed toward the inside of the capsule 200, and the first buckle ring 231 and the second buckle ring 232 can be combined and buckled together to form the buckle ring structure 230.

[0110] The adhesive structure 240 is located in an overlapped area (not shown) between the first capsule shell 210 and the second capsule shell 220. In the capsule 200, the number of the adhesive structure 240 is one.

[0111] In the capsule 200 , the adhesive structure 240 is disposed in the overlapped area and close to the first open end 211 of the first capsule shell 210 , and the buckle ring structure 230 is disposed adjacent to the adhesive structure 240 and close to the second open end 221 of the second capsule shell 220 .

[0112] The additive 202 is contained in the inner space 201 , and the additive 202 includes at least one particle.

[0113] Please also refer to Figure 2 Table 2A shows parameter values ​​of the capsule 200 according to the second embodiment.

[0114]

[0115] Please refer to Table 2B, which shows the type and composition of the particles of the additive 202 of the capsule 200 of the second embodiment, wherein the additive 202 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0116]

[0117] <Third Embodiment>

[0118] Please refer to Figure 3 , which is a schematic diagram of a capsule 300 according to the third embodiment of the present disclosure. The capsule 300 comprises a first capsule shell 310 , a second capsule shell 320 , a buckling ring structure 330 , an adhesive structure 340 and an additive 302 .

[0119] The first capsule shell 310 has a first open end 311 and a first closed end 312 .

[0120] The second capsule shell 320 is correspondingly connected to the first capsule shell 310 , wherein the second capsule shell 320 has a second open end 321 and a second closed end 322 , and the first open end 311 of the first capsule shell 310 is correspondingly connected to the second open end 321 of the second capsule shell 320 to form an internal space 301 .

[0121] The buckle ring structure 330 is disposed on the first capsule shell 310 and the second capsule shell 320. Specifically, the buckle ring structure 330 includes a first buckle ring 331 and a second buckle ring 332, the first buckle ring 331 is disposed on the first capsule shell 310, and the second buckle ring 332 is disposed on the second capsule shell 320. The first buckle ring 331 is an annular structure recessed toward the inside of the capsule 300, and the second buckle ring 332 is also an annular structure recessed toward the inside of the capsule 300, and the first buckle ring 331 and the second buckle ring 332 can be combined and buckled together to form the buckle ring structure 330.

[0122] The first capsule shell 310 may include at least one first rotation stop point 313, and the second capsule shell 320 may include at least one second rotation stop point 323, wherein the first rotation stop point 313 is recessed toward the inside of the capsule 300, and the second rotation stop point 323 is recessed toward the inside of the capsule 300, so that the first rotation stop point 313 on the first capsule shell 310 and the second rotation stop point 323 on the second capsule shell 320 can be combined and buckled with each other. Furthermore, in the capsule 300, the number of the first rotation stop points 313 is six, and the number of the second rotation stop points 323 is six.

[0123] The adhesive structure 340 is located in an overlapped area (not shown) between the first capsule shell 310 and the second capsule shell 320. In the capsule 300, the number of the adhesive structure 340 is one.

[0124] In the capsule 300 , the adhesive structure 340 is disposed in the overlapped area and close to the second open end 321 of the second capsule shell 320 , and the buckle ring structure 330 is disposed adjacent to the adhesive structure 340 and further away from the second open end 321 of the second capsule shell 320 than the adhesive structure 340 .

[0125] The additive 302 is contained in the inner space 301 , and the additive 302 includes at least one particle.

[0126] Please also refer to Figure 3 Table 3A shows parameter values ​​of the capsule 300 according to the third embodiment.

[0127]

[0128]

[0129] Please refer to Table 3B, which shows the type and composition of the particles of the additive 302 of the capsule 300 of the third embodiment, wherein the additive 302 includes eye protection ingredient particles and weight loss ingredient particles.

[0130]

[0131] <Fourth Embodiment>

[0132] Please refer to Figure 4 , which is a schematic diagram of a capsule 400 according to the fourth embodiment of the present disclosure. The capsule 400 comprises a first capsule shell 410 , a second capsule shell 420 , a buckling ring structure 430 , an adhesive structure 440 and an additive 402 .

[0133] The first capsule shell 410 has a first open end 411 and a first closed end 412 .

[0134] The second capsule shell 420 is correspondingly connected to the first capsule shell 410 , wherein the second capsule shell 420 has a second open end 421 and a second closed end 422 , and the first open end 411 of the first capsule shell 410 is correspondingly connected to the second open end 421 of the second capsule shell 420 to form an internal space 401 .

[0135] The buckle ring structure 430 is disposed on the first capsule shell 410 and the second capsule shell 420. Specifically, the buckle ring structure 430 includes a first buckle ring 431 and a second buckle ring 432, the first buckle ring 431 is disposed on the first capsule shell 410, and the second buckle ring 432 is disposed on the second capsule shell 420. The first buckle ring 431 is an annular structure recessed toward the inside of the capsule 400, and the second buckle ring 432 is also an annular structure recessed toward the inside of the capsule 400, and the first buckle ring 431 and the second buckle ring 432 can be combined and buckled together to form the buckle ring structure 430.

[0136] The first capsule shell 410 may include at least one first anti-rotation point 413, and the second capsule shell 420 may include at least one second anti-rotation point 423, wherein the first anti-rotation point 413 is recessed toward the interior of the capsule 400, and the second anti-rotation point 423 is recessed toward the interior of the capsule 400, so that the first anti-rotation point 413 on the first capsule shell 410 and the second anti-rotation point 423 on the second capsule shell 420 can be combined and buckled with each other. Furthermore, in the capsule 400, the number of the first anti-rotation point 413 is two, and the number of the second anti-rotation point 423 is two, wherein the two first anti-rotation points 413 have different shapes, the two second anti-rotation points 423 have different shapes, and the first anti-rotation point 413 and the second anti-rotation point 423 having the same shape are buckled with each other.

[0137] The adhesive structure 440 is located in an overlapped area (not shown) between the first capsule shell 410 and the second capsule shell 420. In the capsule 400, the number of the adhesive structure 440 is one.

[0138] In the capsule 400 , the adhesive structure 440 is disposed in the overlapped area and close to the first open end 411 of the first capsule shell 410 , and the buckle ring structure 430 is disposed at the second open end 421 of the capsule 400 close to the second capsule shell 420 .

[0139] The additive 402 is contained in the inner space 401 , and the additive 402 includes at least one particle.

[0140] Please also refer to Figure 4 Table 4A shows parameter values ​​of the capsule 400 according to the fourth embodiment.

[0141]

[0142] Please refer to Table 4B, which shows the type and composition of the particles of the additive 402 of the capsule 400 of the fourth embodiment, wherein the additive 402 includes eye protection ingredient particles and liver protection ingredient particles.

[0143]

[0144] <Fifth Embodiment>

[0145] Please refer to Figure 5 , which is a schematic diagram of a capsule 500 according to the fifth embodiment of the present disclosure. The capsule 500 comprises a first capsule shell 510 , a second capsule shell 520 , a buckling ring structure 530 , an adhesive structure 540 and an additive 502 .

[0146] The first capsule shell 510 has a first open end 511 and a first closed end 512 .

[0147] The second capsule shell 520 is correspondingly connected to the first capsule shell 510 , wherein the second capsule shell 520 has a second open end 521 and a second closed end 522 , and the first open end 511 of the first capsule shell 510 is correspondingly connected to the second open end 521 of the second capsule shell 520 to form an internal space 501 .

[0148] The buckle ring structure 530 is disposed on the first capsule shell 510 and the second capsule shell 520. Specifically, the buckle ring structure 530 includes a first buckle ring 531 and a second buckle ring 532, wherein the first buckle ring 531 is disposed on the first capsule shell 510, and the second buckle ring 532 is disposed on the second capsule shell 520. The first buckle ring 531 is an annular structure recessed toward the inside of the capsule 500, and the second buckle ring 532 is also an annular structure recessed toward the inside of the capsule 500, and the first buckle ring 531 and the second buckle ring 532 can be assembled and buckled together to form the buckle ring structure 530.

[0149] The first capsule shell 510 may include at least one first rotation stop point 513, and the second capsule shell 520 may include at least one second rotation stop point 523, wherein the first rotation stop point 513 is recessed toward the interior of the capsule 500, and the second rotation stop point 523 is recessed toward the interior of the capsule 500, so that the first rotation stop point 513 on the first capsule shell 510 and the second rotation stop point 523 on the second capsule shell 520 can be combined and buckled with each other. Furthermore, in the capsule 500, the number of the first rotation stop points 513 is four, and the number of the second rotation stop points 523 is four.

[0150] The adhesive structure 540 is located in an overlapped area (not shown) between the first capsule shell 510 and the second capsule shell 520. In the capsule 500, the number of the adhesive structure 540 is one.

[0151] In the capsule 500 , the adhesive structure 540 is disposed in the overlapped area and close to the first open end 511 of the first capsule shell 510 , and the buckle ring structure 530 is disposed at the second open end 521 of the capsule 500 close to the second capsule shell 520 .

[0152] The additive 502 is contained in the inner space 501 , and the additive 502 includes at least one particle.

[0153] Please also refer to Figure 5 Table 5A shows parameter values ​​of the capsule 500 according to the fifth embodiment.

[0154]

[0155] Please refer to Table 5B, which shows the types and compositions of the particles of the additive 502 of the capsule 500 of the fifth embodiment, wherein the additive 502 includes weight loss component particles and liver protection component particles.

[0156]

[0157] <Sixth Embodiment>

[0158] Please refer to Figure 6, which is a schematic diagram of a capsule 600 according to the sixth embodiment of the present disclosure. The capsule 600 comprises a first capsule shell 610 , a second capsule shell 620 , a buckling ring structure 630 , an adhesive structure 640 and an additive 602 .

[0159] The first capsule shell 610 has a first open end 611 and a first closed end 612 .

[0160] The second capsule shell 620 is correspondingly connected to the first capsule shell 610 , wherein the second capsule shell 620 has a second open end 621 and a second closed end 622 , and the first open end 611 of the first capsule shell 610 is correspondingly connected to the second open end 621 of the second capsule shell 620 to form an internal space 601 .

[0161] The buckle ring structure 630 is disposed on the first capsule shell 610 and the second capsule shell 620. Specifically, the buckle ring structure 630 includes a first buckle ring 631 and a second buckle ring 632, the first buckle ring 631 is disposed on the first capsule shell 610, and the second buckle ring 632 is disposed on the second capsule shell 620. The first buckle ring 631 is an annular structure recessed toward the inside of the capsule 600, and the second buckle ring 632 is also an annular structure recessed toward the inside of the capsule 600, and the first buckle ring 631 and the second buckle ring 632 can be combined and buckled together to form the buckle ring structure 630.

[0162] The adhesive structure 640 is located in an overlapped area (not shown) between the first capsule shell 610 and the second capsule shell 620. In the capsule 600, the number of the adhesive structure 640 is one.

[0163] In the capsule 600 , the adhesive structure 640 fills the entire overlapped area, and the buckle ring structure 630 overlaps the overlapped area.

[0164] The additive 602 is contained in the inner space 601 , and the additive 602 includes at least one particle.

[0165] Please also refer to Figure 6 Table 6A shows parameter values ​​of the capsule 600 according to the sixth embodiment.

[0166]

[0167] Please refer to Table 6B, which shows the types and compositions of the particles of the additive 602 of the capsule 600 of the sixth embodiment, wherein the additive 602 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0168]

[0169] <Seventh Embodiment>

[0170] Please refer to Figure 7 , which is a schematic diagram of a capsule 700 according to the seventh embodiment of the present disclosure. The capsule 700 comprises a first capsule shell 710 , a second capsule shell 720 , a buckling ring structure 730 , an adhesive structure 740 and an additive 702 .

[0171] The first capsule shell 710 has a first open end 711 and a first closed end 712 .

[0172] The second capsule shell 720 is correspondingly connected to the first capsule shell 710 , wherein the second capsule shell 720 has a second open end 721 and a second closed end 722 , and the first open end 711 of the first capsule shell 710 is correspondingly connected to the second open end 721 of the second capsule shell 720 to form an internal space 701 .

[0173] The buckle ring structure 730 is disposed on the first capsule shell 710 and the second capsule shell 720. Specifically, the buckle ring structure 730 includes a first buckle ring 731 and a second buckle ring 732, the first buckle ring 731 is disposed on the first capsule shell 710, and the second buckle ring 732 is disposed on the second capsule shell 720. The first buckle ring 731 is an annular structure recessed toward the inside of the capsule 700, and the second buckle ring 732 is also an annular structure recessed toward the inside of the capsule 700, and the first buckle ring 731 and the second buckle ring 732 can be combined and buckled together to form the buckle ring structure 730.

[0174] The first capsule shell 710 may include at least one first rotation stop point 713, and the second capsule shell 720 may include at least one second rotation stop point 723, wherein the first rotation stop point 713 is recessed toward the interior of the capsule 700, and the second rotation stop point 723 is recessed toward the interior of the capsule 700, so that the first rotation stop point 713 on the first capsule shell 710 and the second rotation stop point 723 on the second capsule shell 720 can be combined and buckled with each other. Furthermore, in the capsule 700, the number of the first rotation stop points 713 is four, and the number of the second rotation stop points 723 is four.

[0175] The adhesive structure 740 is located in an overlapped area (not shown) between the first capsule shell 710 and the second capsule shell 720. In the capsule 700, the number of the adhesive structure 740 is one.

[0176] In the capsule 700 , the adhesive structure 740 is disposed in the overlapped region and close to the first open end 711 of the first capsule shell 710 , and the buckle ring structure 730 is disposed close to the second open end 721 of the second capsule shell 720 .

[0177] The additive 702 is contained in the inner space 701 , and the additive 702 includes at least one particle.

[0178] Please also refer to Figure 7 Table 7A shows parameter values ​​of the capsule 700 according to the seventh embodiment.

[0179]

[0180] Please refer to Table 7B, which shows the type and composition of the particles of the additive 702 of the capsule 700 of the seventh embodiment, wherein the additive 702 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0181]

[0182]

[0183] <Eighth Embodiment>

[0184] Please refer to Figure 8 , which is a schematic diagram of a capsule 800 according to the eighth embodiment of the present disclosure. The capsule 800 comprises a first capsule shell 810 , a second capsule shell 820 , a buckling ring structure 830 , an adhesive structure 840 and an additive 802 .

[0185] The first capsule shell 810 has a first open end 811 and a first closed end 812 .

[0186] The second capsule shell 820 is correspondingly connected to the first capsule shell 810 , wherein the second capsule shell 820 has a second open end 821 and a second closed end 822 , and the first open end 811 of the first capsule shell 810 is correspondingly connected to the second open end 821 of the second capsule shell 820 to form an internal space 801 .

[0187] The buckle ring structure 830 is disposed on the first capsule shell 810 and the second capsule shell 820. Specifically, the buckle ring structure 830 includes a first buckle ring 831 and a second buckle ring 832, wherein the first buckle ring 831 is disposed on the first capsule shell 810, and the second buckle ring 832 is disposed on the second capsule shell 820. The first buckle ring 831 is an annular structure recessed toward the inside of the capsule 800, and the second buckle ring 832 is also an annular structure recessed toward the inside of the capsule 800, and the first buckle ring 831 and the second buckle ring 832 can be assembled and buckled together to form the buckle ring structure 830.

[0188] The first capsule shell 810 may include at least one first anti-rotation point 813, and the second capsule shell 820 may include at least one second anti-rotation point 823, wherein the first anti-rotation point 813 is recessed toward the interior of the capsule 800, and the second anti-rotation point 823 is recessed toward the interior of the capsule 800, so that the first anti-rotation point 813 on the first capsule shell 810 and the second anti-rotation point 823 on the second capsule shell 820 can be combined and buckled with each other. Furthermore, in the capsule 800, the number of the first anti-rotation points 813 is four, and the number of the second anti-rotation points 823 is four, wherein the shapes of different first anti-rotation points 813 can be configured to be the same or different, and the shapes of different second anti-rotation points 823 can be configured to be the same or different, and the first anti-rotation points 813 and the second anti-rotation points 823 having the same shape can be buckled with each other.

[0189] The adhesive structure 840 is located in an overlapped area (not shown) between the first capsule shell 810 and the second capsule shell 820. In the capsule 800, the number of the adhesive structure 840 is one.

[0190] In the capsule 800 , the adhesive structure 840 is disposed in the overlapped region and close to the first open end 811 of the first capsule shell 810 , and the buckle ring structure 830 is disposed at the second open end 821 of the capsule 800 close to the second capsule shell 820 .

[0191] The additive 802 is contained in the inner space 801 , and the additive 802 includes at least one particle.

[0192] Please also refer to Figure 8 Table 8A shows parameter values ​​of the capsule 800 according to the eighth embodiment.

[0193]

[0194] Please refer to Table 8B, which shows the type and composition of the particles of the additive 802 of the capsule 800 of the eighth embodiment, wherein the additive 802 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0195]

[0196]

[0197] <Ninth Embodiment>

[0198] Please refer to Fig. 9 , which is a schematic diagram of a capsule 900 according to the ninth embodiment of the present disclosure. The capsule 900 comprises a first capsule shell 910 , a second capsule shell 920 , two buckling ring structures 930 , two adhesive structures 940 and an additive 902 .

[0199] The first capsule shell 910 has a first open end 911 and a first closed end 912 .

[0200] The second capsule shell 920 is correspondingly connected to the first capsule shell 910 , wherein the second capsule shell 920 has a second open end 921 and a second closed end 922 , and the first open end 911 of the first capsule shell 910 is correspondingly connected to the second open end 921 of the second capsule shell 920 to form an internal space 901 .

[0201] The two buckling ring structures 930 are disposed on the first capsule shell 910 and the second capsule shell 920. Specifically, each buckling ring structure 930 includes a first buckling ring 931 and a second buckling ring 932, wherein the first buckling ring 931 is disposed on the first capsule shell 910, and the second buckling ring 932 is disposed on the second capsule shell 920. The first buckling ring 931 is an annular structure recessed toward the inside of the capsule 900, and the second buckling ring 932 is also an annular structure recessed toward the inside of the capsule 900, and the first buckling ring 931 and the second buckling ring 932 of each buckling ring structure 930 can be combined and buckled with each other to form the buckling ring structure 930. In the capsule 900, the two buckling ring structures 930 are respectively located at the first open end 911 of the first capsule shell 910 and the second open end 921 of the second capsule shell 920.

[0202] The first capsule shell 910 may include at least one first rotation stop point 913, and the second capsule shell 920 may include at least one second rotation stop point 923, wherein the first rotation stop point 913 is recessed toward the interior of the capsule 900, and the second rotation stop point 923 is recessed toward the interior of the capsule 900, so that the first rotation stop point 913 on the first capsule shell 910 and the second rotation stop point 923 on the second capsule shell 920 can be combined and buckled with each other. Furthermore, in the capsule 900, the number of the first rotation stop points 913 is two, and the number of the second rotation stop points 923 is two.

[0203] The two viscose structures 940 are located in an overlapping area (not shown) between the first capsule shell 910 and the second capsule shell 920, wherein one viscose structure 940 is disposed in the overlapping area and close to the first opening end 911 of the first capsule shell 910, and the other viscose structure 940 is disposed in the overlapping area and close to the second opening end 921 of the second capsule shell 920, and the two buckling ring structures 930 are respectively adjacent to the two viscose structures 940, and the two buckling ring structures 930 are farther away from the first opening end 911 of the first capsule shell 910 and the second opening end 921 of the second capsule shell 920 than the two viscose structures 940.

[0204] The additive 902 is contained in the inner space 901 , and the additive 902 includes at least one particle.

[0205] Please also refer to Fig. 9Table 9A shows parameter values ​​of the capsule 900 according to the ninth embodiment.

[0206]

[0207] Please refer to Table 9B, which shows the type and composition of the particles of the additive 902 of the capsule 900 of the ninth embodiment, wherein the additive 902 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0208]

[0209]

[0210] <10th Embodiment>

[0211] Please refer to Fig.10 , which is a schematic diagram of a capsule 1000 according to the tenth embodiment of the present disclosure. The capsule 1000 comprises a first capsule shell 1010 , a second capsule shell 1020 , a buckling ring structure 1030 , an adhesive structure 1040 and an additive 1002 .

[0212] The first capsule shell 1010 has a first open end 1011 and a first closed end 1012 .

[0213] The second capsule shell 1020 is correspondingly connected to the first capsule shell 1010 , wherein the second capsule shell 1020 has a second open end 1021 and a second closed end 1022 , and the first open end 1011 of the first capsule shell 1010 is correspondingly connected to the second open end 1021 of the second capsule shell 1020 to form an internal space 1001 .

[0214] The buckle ring structure 1030 is disposed on the first capsule shell 1010 and the second capsule shell 1020. Specifically, the buckle ring structure 1030 includes a first buckle ring 1031 and a second buckle ring 1032, the first buckle ring 1031 is disposed on the first capsule shell 1010, and the second buckle ring 1032 is disposed on the second capsule shell 1020. The first buckle ring 1031 is an annular structure recessed toward the inside of the capsule 1000, and the second buckle ring 1032 is also an annular structure recessed toward the inside of the capsule 1000, and the first buckle ring 1031 and the second buckle ring 1032 can be combined and buckled together to form the buckle ring structure 1030.

[0215] The first capsule shell 1010 may include at least one first anti-rotation point 1013, and the second capsule shell 1020 may include at least one second anti-rotation point 1023, wherein the first anti-rotation point 1013 is recessed toward the interior of the capsule 1000, and the second anti-rotation point 1023 is recessed toward the interior of the capsule 1000, so that the first anti-rotation point 1013 on the first capsule shell 1010 and the second anti-rotation point 1023 on the second capsule shell 1020 can be combined and buckled with each other. Furthermore, in the capsule 1000, the number of the first anti-rotation points 1013 is eight, and the number of the second anti-rotation points 1023 is eight, and the shapes of different first anti-rotation points 1013 can be configured to be the same or different, and the shapes of different second anti-rotation points 1023 can be configured to be the same or different, and the first anti-rotation points 1013 and the second anti-rotation points 1023 having the same shape can be buckled with each other.

[0216] The adhesive structure 1040 is located in an overlapped area (not shown) between the first capsule shell 1010 and the second capsule shell 1020. In the capsule 1000, the number of the adhesive structure 1040 is one.

[0217] In the capsule 1000 , the adhesive structure 1040 is disposed in the overlapped region and close to the first open end 1011 of the first capsule shell 1010 , and the buckle ring structure 1030 is disposed close to the second open end 1021 of the second capsule shell 1020 .

[0218] The additive 1002 is contained in the inner space 1001 , and the additive 1002 includes at least one particle.

[0219] Please also refer to Fig.10 Table 10A shows parameter values ​​of the capsule 1000 according to the tenth embodiment.

[0220]

[0221] Please refer to Table 10B, which shows the type and composition of the particles of the additive 1002 of the capsule 1000 of the tenth embodiment, wherein the additive 1002 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0222]

[0223]

[0224] <11th embodiment>

[0225] Please refer to Fig.11 , which is a schematic diagram of a capsule 1100 according to the eleventh embodiment of the present disclosure. The capsule 1100 comprises a first capsule shell 1110 , a second capsule shell 1120 , two buckled ring structures 1130 and an additive 1102 .

[0226] The first capsule shell 1110 has a first open end 1111 and a first closed end 1112 .

[0227] The second capsule shell 1120 is correspondingly connected to the first capsule shell 1110 , wherein the second capsule shell 1120 has a second open end 1121 and a second closed end 1122 , and the first open end 1111 of the first capsule shell 1110 is correspondingly connected to the second open end 1121 of the second capsule shell 1120 to form an internal space 1101 .

[0228] The two buckling ring structures 1130 are disposed on the first capsule shell 1110 and the second capsule shell 1120. Specifically, each buckling ring structure 1130 includes a first buckling ring 1131 and a second buckling ring 1132, wherein the first buckling ring 1131 is disposed on the first capsule shell 1110, and the second buckling ring 1132 is disposed on the second capsule shell 1120. The first buckling ring 1131 is an annular structure recessed toward the interior of the capsule 1100, and the second buckling ring 1132 is also an annular structure recessed toward the interior of the capsule 1100, and the first buckling ring 1131 and the second buckling ring 1132 can be combined and buckled with each other to form the buckling ring structure 1130. In the capsule 1100, the two buckling ring structures 1130 are respectively disposed adjacent to the first open end 1111 of the first capsule shell 1110 and the second open end 1121 of the second capsule shell 1120.

[0229] The first capsule shell 1110 may include at least one first anti-rotation point 1113, and the second capsule shell 1120 may include at least one second anti-rotation point 1123, wherein the first anti-rotation point 1113 is recessed toward the interior of the capsule 1100, and the second anti-rotation point 1123 is recessed toward the interior of the capsule 1100, so that the first anti-rotation point 1113 on the first capsule shell 1110 and the second anti-rotation point 1123 on the second capsule shell 1120 can be combined and buckled with each other. Furthermore, in the capsule 1100, the number of the first anti-rotation point 1113 is two, and the number of the second anti-rotation point 1123 is two.

[0230] The additive 1102 is contained in the inner space 1101 , and the additive 1102 includes at least one particle.

[0231] Please also refer to Fig.11 Table 11A shows parameter values ​​of the capsule 1100 according to the eleventh embodiment.

[0232]

[0233] Please refer to Table 11B, which shows the type and composition of the particles of the additive 1102 of the capsule 1100 of the eleventh embodiment, wherein the additive 1102 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0234]

[0235] <12th embodiment>

[0236] Please refer to Fig.12 , which is a schematic diagram of a capsule 1200 according to the twelfth embodiment of the present disclosure. The capsule 1200 comprises a first capsule shell 1210 , a second capsule shell 1220 , a buckling ring structure 1230 and an additive 1202 .

[0237] The first capsule shell 1210 has a first open end 1211 and a first closed end 1212 .

[0238] The second capsule shell 1220 is correspondingly connected to the first capsule shell 1210 , wherein the second capsule shell 1220 has a second open end 1221 and a second closed end 1222 , and the first open end 1211 of the first capsule shell 1210 is correspondingly connected to the second open end 1221 of the second capsule shell 1220 to form an internal space 1201 .

[0239] The buckle ring structure 1230 is disposed on the first capsule shell 1210 and the second capsule shell 1220. Specifically, the buckle ring structure 1230 includes a first buckle ring 1231 and a second buckle ring 1232, the first buckle ring 1231 is disposed on the first capsule shell 1210, and the second buckle ring 1232 is disposed on the second capsule shell 1220. The first buckle ring 1231 is an annular structure recessed toward the inside of the capsule 1200, and the second buckle ring 1232 is also an annular structure recessed toward the inside of the capsule 1200, and the first buckle ring 1231 and the second buckle ring 1232 can be combined and buckled together to form the buckle ring structure 1230.

[0240] The first capsule shell 1210 may include at least one first anti-rotation point 1213, and the second capsule shell 1220 may include at least one second anti-rotation point 1223, wherein the first anti-rotation point 1213 is recessed toward the interior of the capsule 1200, and the second anti-rotation point 1223 is recessed toward the interior of the capsule 1200, so that the first anti-rotation point 1213 on the first capsule shell 1210 and the second anti-rotation point 1223 on the second capsule shell 1220 can be combined and buckled with each other. Furthermore, in the capsule 1200, the number of the first anti-rotation points 1213 is eight, and the number of the second anti-rotation points 1223 is eight, and the shapes of different first anti-rotation points 1213 can be configured to be the same or different, and the shapes of different second anti-rotation points 1223 can be configured to be the same or different, and the first anti-rotation points 1213 and the second anti-rotation points 1223 having the same shape can be buckled with each other.

[0241] The additive 1202 is contained in the inner space 1201 , and the additive 1202 includes at least one particle.

[0242] Please also refer to Fig.12 Table 12A shows parameter values ​​of the capsule 1200 according to the twelfth embodiment.

[0243]

[0244]

[0245] Please refer to Table 12B, which shows the type and composition of the particles of the additive 1202 of the capsule 1200 of the twelfth embodiment, wherein the additive 1202 includes eye protection ingredient particles, weight loss ingredient particles, and liver protection ingredient particles.

[0246]

[0247] Although the present disclosure has been disclosed in the above implementation mode, it is not intended to limit the present disclosure. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the scope of protection of the present disclosure should be determined by the attached claims.

Claims

1. A capsule, characterized in that: Include: a first capsule shell having a first open end and a first closed end; A second capsule shell, correspondingly connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end; A buckling ring structure is disposed on the first capsule shell and the second capsule shell; and an adhesive structure located in an overlapped area between the first capsule shell and the second capsule shell; The maximum width of the buckle ring structure is Wcmax, the maximum length of the first capsule shell is W1, the maximum length of the second capsule shell is W2, and the width of the overlapping area between the first capsule shell and the second capsule shell is Wo12, which meets the following conditions: 0≤Wcmax / (W1+W2-Wo12)≤2.

2. The capsule according to claim 1, characterized in that The first capsule shell includes at least one first rotation stop point, and the second capsule shell includes at least one second rotation stop point.

3. The capsule according to claim 2, characterized in that The first rotation-stopping point of the first capsule shell is recessed toward the interior of the capsule, and the second rotation-stopping point of the second capsule shell is recessed toward the interior of the capsule.

4. The capsule according to claim 3, characterized in that The number of the first anti-rotation points of the first capsule shell is N1, and the number of the second anti-rotation points of the second capsule shell is N2, which satisfies the following conditions: 0≤N1+N2≤20.

5. The capsule according to claim 1, characterized in that: The buckling ring structure includes a first buckling ring and a second buckling ring, the first buckling ring is disposed on the first capsule shell, and the second buckling ring is disposed on the second capsule shell; and The outer diameter of the first open end of the first capsule shell is D1, and the minimum diameter of the buckle ring structure is Dcmin, which meets the following conditions: 0 <Dcmin / D1<1。 6. The capsule according to claim 1, characterized in that The width of the adhesive structure is Wgl, and the width of the overlapped area between the first capsule shell and the second capsule shell is Wo12, which satisfies the following conditions: 0 <Wgl / Wo12≤5。 7. The capsule according to claim 1, characterized in that Also includes: an interior space; and At least one additive is placed in the internal space, wherein the at least one additive comprises at least one particle, and the at least one particle is a sleep-promoting ingredient particle, an anti-aging ingredient particle, an eye-protecting ingredient particle, a weight-loss ingredient particle, a liver-protecting ingredient particle, or a cardiovascular-benefiting ingredient particle.

8. The capsule according to claim 7, characterized in that Also includes: A film coating structure is arranged on the outer sides of the first capsule shell and the second capsule shell.

9. A capsule, characterized in that: Include: a first capsule shell having a first open end and a first closed end; A second capsule shell, correspondingly connected to the first capsule shell, and the second capsule shell has a second open end and a second closed end; A buckle ring structure is disposed on the first capsule shell and the second capsule shell; an internal space formed by correspondingly connecting the first capsule shell and the second capsule shell; and At least one additive is contained in the internal space, and the at least one additive comprises at least one particle; The maximum width of the buckle ring structure is Wcmax, the maximum length of the first capsule shell is W1, the maximum length of the second capsule shell is W2, and the width of an overlapping area between the first capsule shell and the second capsule shell is Wo12, which meets the following conditions: 0 <Wcmax / (W1+W2-Wo12)≤0.4。 10. The capsule according to claim 9, characterized in that: The buckling ring structure includes a first buckling ring and a second buckling ring, the first buckling ring is disposed on the first capsule shell, and the second buckling ring is disposed on the second capsule shell; and The outer diameter of the first open end of the first capsule shell is D1, and the minimum diameter of the buckle ring structure is Dcmin, which meets the following conditions: 0.5≤Dcmin / D1≤1.

5.

11. The capsule according to claim 9, characterized in that Also includes: A viscose structure is located in the overlapped area between the first capsule shell and the second capsule shell, wherein the width of the viscose structure is Wgl, and the width of the overlapped area between the first capsule shell and the second capsule shell is Wo12, which satisfies the following conditions: 0≤Wgl / Wo12≤1.

12. The capsule according to claim 9, characterized in that The at least one particle is a sleep-promoting ingredient particle, an anti-aging ingredient particle, an eye-protecting ingredient particle, a weight-loss ingredient particle, a liver-protecting ingredient particle, or a cardiovascular-benefiting ingredient particle.

13. The capsule according to claim 12, characterized in that The at least one particle is the eye protection component particle.

14. The capsule according to claim 12, wherein The at least one particle is the weight-reducing component particle.

15. The capsule according to claim 12, wherein The at least one particle is the liver protecting component particle.

16. The capsule according to claim 12, wherein The at least one particle is the sleep-relief component particle.

17. The capsule according to claim 12, wherein The at least one particle is the anti-aging ingredient particle.

18. The capsule according to claim 12, wherein The at least one particle is the cardiovascular beneficial ingredient particle.

19. The capsule according to claim 12, wherein Also includes: A film coating structure is arranged on the outer sides of the first capsule shell and the second capsule shell.

Images